Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Individualization of Abdominopelvic CT Protocols With Lower Tube Voltage to Reduce IV Contrast Dose or Radiation Dose
Hough, David M., Yu, Lifeng , Shiung, Maria M., Carter, Rickey E. , Geske, Jennifer R. , Fidler, Jeff L. , Huprich, James E., Jondal, Dayna, Yu, Lifeng , Leng, Shuai , Fidler, Jeff L. , McCollough, Cynthia H. , Fletcher, Joel G. , Carter, Rickey E , Geske, Jennifer

American Journal of Roentgenology | June 21, 2013 | Volume: 201 | Issue: 1 | Pages: 147-153

10.2214/ajr.12.9295 | PMID 23789669 Get It

Multiphase CT Enterography Evaluation of Small-Bowel Vascular Lesions
Huprich, James E., Barlow, John M. , Hansel, Stephanie L. , Alexander, Jeffrey A. , Fidler, Jeff L. , Fidler, Jeff L. , Hansel, Stephanie L

American Journal of Roentgenology | June 21, 2013 | Volume: 201 | Issue: 1 | Pages: 65-72

10.2214/ajr.12.10414 | PMID 23789659 Get It

Two-Tiered Approach to MRI for Headache: A Cost-Effective Way to Use an Expensive Technology
Sharma, Aseem , Reis, Martin, Wippold, Franz J. , Chrisinger, John S.A. , Schwedt, Todd J. , Pilgram, Thomas K., Parsons, Matthew S. , Schwedt, Todd J , Chrisinger, John S A

American Journal of Roentgenology | June 21, 2013 | Volume: 201 | Issue: 1 | Pages: W75-W80

10.2214/ajr.12.10238 | PMID 23789700 Get It

Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bhangu, Aneel , Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Hompes, Roel , Jeys, Lee , Jenkins, John T. , Kiran, Ravi P. , Koh, Cherry , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Patel, Uday , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tan, Emile , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Collaborative, The Beyond TME, Ali, Simak , Brown, Gina , Wilt, Johannes H.W. de , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Glynne‐Jones, Rob , Goldin, Robert , Harji, Deena Pravin , Heriot, Alexander G. , Marshall, Michelle Berger , Radley, Simon, Solomon, Michael J. , Jeys, Lee M

British Journal of Surgery | June 21, 2013 | Volume: 100 | Issue: 8 | Pages: E1-E33

10.1002/bjs.9192_1 | PMID 23901427 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Use of a Poroelastic Model to Predict Intramuscular Pressure
Morrow, Duane A., Odegard, Gregory M. , Kaufman, Kenton R. , Kaufman, Kenton R

Poromechanics V | June 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: 2174-2183

10.1061/9780784412992.256 | PMID 25541627 Get It

Radiation Exposure in the Cardiac Catheterization Lab
Levy, Michael S. , Kumar, Preetham

Catheterization and Cardiovascular Interventions | June 21, 2013 | Volume: 82 | Issue: 1 | Pages: 17-18

10.1002/ccd.25027 | PMID 23788383 Get It

Contribution of nitric oxide in the contraction-induced rapid vasodilation in young and older adults
Casey, Darren P. , Walker, Branton G., Ranadive, Sushant M. , Taylor, Jennifer L. , Joyner, Michael J. , Ranadive, Sushant

Journal of Applied Physiology | June 21, 2013 | Volume: 115 | Issue: 4 | Pages: 446-455

10.1152/japplphysiol.00446.2013 | PMID 23788575 Get It

We tested the hypothesis that reduced nitric oxide (NO) bioavailability contributes to the attenuated peak and total vasodilation following single-muscle contractions in older adults. Young ( n = 10; 24 ± 2 yr) and older ( n = 10; 67 ± 2 yr) adults performed single forearm contractions at 10, 20, and 40% of maximum during saline infusion (control) and NO synthase (NOS) inhibition via NG-monomethyl-l-arginine. Brachial artery diameters and velocities were measured using Doppler ultrasound and forearm vascular conductance (FVC; in ml·min−1·100 mmHg−1) was calculated from blood flow (ml/min) and blood pressure (mmHg). Peak and total vasodilator responses [change (Δ) in FVC from baseline] were attenuated in older adults at all intensities ( P < 0.05). NOS inhibition reduced the peak ΔFVC at 10% (88 ± 12 vs. 52 ± 9 ml·min−1·100 mmHg−1), 20% (125 ± 13 vs. 83 ± 13 ml·min−1·100 mmHg−1), and 40% (207 ± 26 vs. 133 ± 20 ml·min−1·100 mmHg−1) in young subjects, ( P < 0.05 for all) and in older adults at 10% (59 ± 5 vs. 47 ± 7 ml·min−1·100 mmHg−1, P < 0.05) and 20% (88 ± 9 vs. 68 ± 9 ml·min−1·100 mmHg−1, P < 0.05), but not 40% (128 ± 12 vs. 105 ± 11 ml·min−1·100 mmHg−1, P = 0.11). The relative (%) reduction in peak ΔFVC due to NOS inhibition was greater in young vs. older adults at 20% (−36 ± 5 vs. −23 ± 5%, P < 0.05) and 40% (−35 ± 6 vs. −16 ± 7%, P < 0.05). The reduction in the total vasodilator response (area under the curve) with NOS inhibition was also greater in young vs. older adults at all intensities. Our data suggest that contraction-induced rapid vasodilation is mediated in part by NO, and that the contribution of NO is greater in young adults.
Pharmacogenetics in dermatology: a patient‐centered update
Comfere, Nneka I. , Ikediobi, Ogechi , Peters, Margot S. , el‐Azhary, Rokea A. , Gibson, Lawrence E. , El-Azhary, Rokea

International Journal of Dermatology | June 21, 2013 | Volume: 52 | Issue: 8 | Pages: 1005-1012

10.1111/j.1365-4632.2012.05793.x | PMID 23786543 Get It

AbstractBackgroundThe term pharmacogenetics is used to describe an evolving field that aims to understand the relationship between individual variations in genetic sequence and differences in the therapeutic and toxic response to medications. The promise of pharmacogenetics is empowerment of clinicians with information that will enable them to personalize drug therapy – to prescribe the right medication at the right dose for each patient, while minimizing adverse effects. Despite dramatic advances, wide application of pharmacogenetics to clinical practice has been slow for a number of reasons, including lack of evidence‐based therapeutic guidelines as well as ethical concerns and cost.MethodsTo illustrate applications to dermatology practice, we present three clinical scenarios that serve as a springboard for discussion of the principles of pharmacogenetics and how they can be used to guide treatment with azathioprine, 5‐fluorouracil, and trastuzumab.ConclusionThe therapeutic and toxic effects of a given medication ultimately depend on its combined pharmacokinetic, pharmacodynamic, and pharmacogenetic properties in a given individual. Pharmacodynamic properties of individual medications must be correlated with single nucleotide polymorphisms. Test recommendations and standardization of therapy for specific disorders can then be established.
Stem cell transplantation in non-Hodgkin lymphomas
Friedberg, Jonathan W. , Hashmi, Shahrukh K.

Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies | June 20, 2013 | Volume: No volume available | Issue: No issue available | Pages: 182-195

10.2217/ebo.12.116 Get It

Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management
Gertz, Morie A.

American Journal of Hematology | June 20, 2013 | Volume: 88 | Issue: 8 | Pages: 703-711

10.1002/ajh.23472 | PMID 23784973 Get It

Disease OverviewWaldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy.DiagnosisThe presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis.Risk StratificationAge, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis.Risk‐Adapted TherapyNot all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐based therapy is used in virtually all US patients with WM and can be combined with alkylating agent or purine nucleoside analog (or both). The preferred Mayo Clinic nonstudy therapeutic induction is rituximab, cyclophosphamide, and dexamethasone. Future stem cell transplantation should be considered in induction therapy selection.Management of Refractory DiseaseBortezomib, thalidomide, everolimus, lenalidomide, and bendamustine have all been shown to have activity in WM. Given WM's natural history, reduction of complications will be a priority for future treatment trials. Am. J. Hematol. 88:703–711, 2013. © 2013 Wiley Periodicals, Inc.